Agenus Inc. (AGEN)

Agenus's stock price has fluctuated, with a 52-week high of $7.34 on July 11, 2025, and a low of $1.38 on April 7, 2025; as of February 5, 2026, it was $2.77. Key events include Q3 2025 earnings missing expectations, a $141 million strategic collaboration with Zydus Lifesciences involving the sale of Agenus's CDMO business and a licensing agreement, France expanding national AAC access for BOT+BAL, publication of BOT+BAL clinical results, a stakeholder webcast, and a collaboration with Noetik to develop AI-enabled predictive biomarkers.

Demand for Agenus's products and services is driven by medical need, clinical trial progress, and regulatory approvals, rather than seasonal patterns. Disease prevalence, clinical trial success, partnerships, and healthcare spending influence demand.

Agenus, Inc., a clinical-stage biotechnology company based in Lexington, Massachusetts, specializes in discovering and developing immunotherapies for cancer and infectious diseases, operating within the biotechnology and pharmaceutical sectors with a focus on immuno-oncology. Its portfolio includes checkpoint modulators like botensilimab and balstilimab, prophage vaccines in Phase 2 studies, the QS-21 Stimulon™ Adjuvant used in partnered vaccines, and the Retrocyte Display® Technology for antibody discovery.

Agenus operates globally with its headquarters in Lexington, Massachusetts, serving as the central hub for operations. The company has a presence in North America and Europe, facilitating collaborations and access to diverse clinical trial populations. In January 2026, Agenus expanded into India and Sri Lanka through a licensing agreement with Zydus Lifesciences for its botensilimab and balstilimab products.

Agenus's brand reputation has been positively influenced by advancements in immuno-oncology, particularly the botensilimab and balstilimab program, positioning the company as a leader in immuno-oncology innovation. Positive clinical data and publications, strategic collaborations and market expansion, regulatory access, and a focus on innovation have contributed to this reputation.

Agenus Inc.'s ownership is characterized by significant institutional investment, with 30.11% held by institutions as of early November 2025; major holders include Vanguard Group Inc., Siren, L.L.C., and BlackRock, Inc. Insider ownership, representing management and board members, was relatively small at 1.71%.